{
    "id": "9d39ab3d-b86c-404f-b5e7-ee3fb3aa2864",
    "indications": "SYMBRAVO is indicated for the acute treatment of migraine with or without aura in adults.\n                  \n                     Limitations of Use\n                  \n                  \n                     SYMBRAVO should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with SYMBRAVO, the diagnosis of migraine should be reconsidered before SYMBRAVO is administered to treat any subsequent attacks.\n                     SYMBRAVO is not indicated for the preventive treatment of migraine attacks.\n                     SYMBRAVO is not indicated for the treatment of cluster headache.",
    "contraindications": "The recommended dose of SYMBRAVO is one tablet by mouth as needed ( 2.1 ). The maximum daily dose is 20 mg meloxicam and 10 mg rizatriptan (1 tablet) ( 2.1 ).",
    "warningsAndPrecautions": "16.1 How Supplied\n                  \n                  SYMBRAVO tablets are white, modified capsule-shaped, film-coated and debossed with \"MXRZ\" on one side and \"20/10\" on the other. SYMBRAVO is supplied in the following package configuration:\n                  \n                     \n                     \n                        \n                           \n                               Package Configuration\n                           \n                           \n                               Strength\n                           \n                           \n                               NDC Code\n                           \n                        \n                        \n                            Bottles of 9 tablets\n                            meloxicam 20 mg and rizatriptan 10 mg\n                            81968-020-09\n                        \n                     \n                  \n                  \n                     16.2 Storage and Handling\n                  \n                  Store SYMBRAVO in the original bottle at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "SYMBRAVO is contraindicated in patients with:\n                  \n                     Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see \n                        \n                           Warnings & Precautions (5.1)\n                        \n                        ].\n                     Coronary artery vasospasm including Prinzmetal’s angina [see \n                        \n                           Warnings & Precautions (5.1)\n                        \n                        ].\n                     In the setting of coronary artery bypass graft (CABG) surgery [see Warnings & Precautions (5.1)].\n                     History of stroke or transient ischemic attack (TIA) [see Warnings & Precautions (5.4)].\n                     Hemiplegic or basilar migraine.\n                     Peripheral vascular disease (PVD) [see Warnings & Precautions (5.7)].\n                     Ischemic bowel disease [see Warnings & Precautions (5.7)].\n                     Uncontrolled hypertension [see Warnings & Precautions (5.9)].\n                     Concomitant use of propranolol [see Drug Interactions (7.1)]\n                     \n                     Recent use (i.e., within 24 hours) of an ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-HT1 agonist (e.g., another triptan) [see Drug Interactions (7.1)].\n                     Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].\n                     Known hypersensitivity (e.g., anaphylactic reactions and angioedema seen) to SYMBRAVO, meloxicam, rizatriptan, NSAIDs or any of the excipients in SYMBRAVO [see Warnings & Precautions (5.5), Adverse Reactions (6.2)].\n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal anaphylactic-like reactions to NSAIDs have been reported in such patients [see Warnings & Precautions (5.16)].\n                     Moderate to severe renal insufficiency in patients who are at risk for renal failure due to volume depletion or who are on dialysis [see Warnings & Precautions (5.11)].",
    "ingredients": [
        {
            "name": "MELOXICAM",
            "code": "VG2QF83CGL"
        },
        {
            "name": "RIZATRIPTAN BENZOATE",
            "code": "WR978S7QHH"
        },
        {
            "name": "BETADEX SULFOBUTYL ETHER SODIUM",
            "code": "2PP9364507"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        }
    ],
    "organization": "Axsome Therapeutics, Inc.",
    "name": "SYMBRAVO",
    "effectiveTime": "20250224"
}